Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose vs Standard-dose Bevacizumab for Type 1 ROP
NCT05712642Phase 3Completed
- Sponsor
- Cairo University
- Start
- Feb 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in retinopathy of prematurity (ROP), sponsored by Cairo University. Started Feb 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on NCT05712642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712642.